Top news of the week: 04.11.2022.
CSL stacks up $4.5B in chips — with a $200M ante — to wager on the next-gen mRNA wave
Australian pharma giant CSL is making a late bid for mRNA glory, and they’ve lined up one of the also-ran US Covid-19 biotechs touting their own particular tech twist to partner with. CSL ...
Nucleate Boston partners with the Massachusetts Life Science Center to support the formation of early-stage biotech ventures
Massachusetts Life Sciences Center extends grant to Nucleate Boston’s Activator Program to support promising early stage technology…
Ambrx Biopharma Inc. Appoints Daniel O’Connor as Chief Executive Officer
SAN DIEGO--(BUSINESS WIRE)--Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered ...
Mysterious OrbiMed-backed biotech nears $100M in funding, hints at plans to go after ‘undruggable 3.0’
In January, Alterome launched from stealth — but remained quite stealthy. While the biotech put out a press release for its $64 million Series A, led by OrbiMed, it launched without a ...
Here’s why we’re not prepared for the next wave of biotech innovation
This is "biology's century," @matthewherper writes. But we’re approaching a moment when changes in what we understand are every bit as terrifying as exhilarating.
Under hub-and-spoke biotech, serial founders launch new startup hoping to make gene therapies for the eye
In late July, Sangamo’s former R&D chief Adrian Woolfson, who left the biotech when it split its R&D, launched his own gene therapy outfit. Replay’s primary platform was an HSV vector ...
Exclusive: Mt. Everest almost got in the way of a tRNA biotech, but hC Bioscience climbs to Series A extension
A Takeda and ARCH-backed startup looking to prove out the next potential RNA goldmine in drug R&D has secured more capital en route to a 2024 clinical entry, CEO Leslie Williams tells ...
In spinning out cancer pipeline, Alkermes cites Inflation Reduction Act's hypothetical incentives for biologics R&D
Alkermes announced Wednesday morning it would siphon off its burgeoning oncology business, and cited one of President Joe Biden’s signature pieces of legislation as a motivator. The Irish ...